These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 11272290

  • 1. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
    Arencibia JM, Schally AV, Halmos G, Nagy A, Kiaris H.
    Anticancer Drugs; 2001 Jan; 12(1):71-8. PubMed ID: 11272290
    [Abstract] [Full Text] [Related]

  • 2. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
    Nagy A, Schally AV.
    Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
    [Abstract] [Full Text] [Related]

  • 3. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J, Emons G, Pinski J, Schally AV.
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [Abstract] [Full Text] [Related]

  • 4. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
    Arencibia JM, Bajo AM, Schally AV, Krupa M, Chatzistamou I, Nagy A.
    Anticancer Drugs; 2002 Oct; 13(9):949-56. PubMed ID: 12394258
    [Abstract] [Full Text] [Related]

  • 5. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
    Gründker C, Völker P, Griesinger F, Ramaswamy A, Nagy A, Schally AV, Emons G.
    Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
    [Abstract] [Full Text] [Related]

  • 6. Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness.
    Arencibia JM, Schally AV, Krupa M, Bajo AM, Nagy A, Szepeshazi K, Plonowski A.
    Int J Oncol; 2001 Sep; 19(3):571-7. PubMed ID: 11494038
    [Abstract] [Full Text] [Related]

  • 7. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
    Kahán Z, Nagy A, Schally AV, Halmos G, Arencibia JM, Groot K.
    Breast Cancer Res Treat; 2000 Feb; 59(3):255-62. PubMed ID: 10832595
    [Abstract] [Full Text] [Related]

  • 8. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
    Emons G, Sindermann H, Engel J, Schally AV, Gründker C.
    Neuroendocrinology; 2009 Feb; 90(1):15-8. PubMed ID: 19521066
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A, Schally AV, Nagy A, Szepeshazi K, Kanashiro CA, Halmos G.
    Prostate; 2006 Feb 01; 66(2):200-10. PubMed ID: 16173040
    [Abstract] [Full Text] [Related]

  • 10. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
    Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser HP, Nagy A, Schulz KD, Grundker C, Schally AV, Emons G.
    Int J Oncol; 2000 Nov 01; 17(5):1063-9. PubMed ID: 11029513
    [Abstract] [Full Text] [Related]

  • 11. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB, Keller G, Schally AV, Nagy A, Chism DD, Halmos G.
    Fertil Steril; 2005 Apr 01; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [Abstract] [Full Text] [Related]

  • 12. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
    Oláh G, Dobos N, Vámosi G, Szabó Z, Sipos É, Fodor K, Harda K, Schally AV, Halmos G.
    Eur J Pharm Sci; 2018 Oct 15; 123():371-376. PubMed ID: 30076951
    [Abstract] [Full Text] [Related]

  • 13. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
    Milovanovic SR, Monje E, Szepeshazi K, Radulovic S, Schally A.
    J Cancer Res Clin Oncol; 1993 Oct 15; 119(5):273-8. PubMed ID: 8382705
    [Abstract] [Full Text] [Related]

  • 14. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
    Koppán M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, Groot K.
    Prostate; 1999 Feb 01; 38(2):151-8. PubMed ID: 9973101
    [Abstract] [Full Text] [Related]

  • 15. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    Seitz S, Buchholz S, Schally AV, Weber F, Klinkhammer-Schalke M, Inwald EC, Perez R, Rick FG, Szalontay L, Hohla F, Segerer S, Kwok CW, Ortmann O, Engel JB.
    BMC Cancer; 2014 Nov 19; 14():847. PubMed ID: 25410881
    [Abstract] [Full Text] [Related]

  • 16. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR, Gründker C, Bongertz T, Schlott T, Nagy A, Schally AV, Emons G.
    Am J Obstet Gynecol; 2004 Oct 19; 191(4):1164-72. PubMed ID: 15507937
    [Abstract] [Full Text] [Related]

  • 17. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
    Miyazaki M, Schally AV, Nagy A, Lamharzi N, Halmos G, Szepeshazi K, Armatis P.
    Am J Obstet Gynecol; 1999 May 19; 180(5):1095-103. PubMed ID: 10329861
    [Abstract] [Full Text] [Related]

  • 18. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
    Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, Groot K, Armatis P.
    J Natl Cancer Inst; 1997 Dec 03; 89(23):1803-9. PubMed ID: 9392622
    [Abstract] [Full Text] [Related]

  • 19. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
    Föst C, Duwe F, Hellriegel M, Schweyer S, Emons G, Gründker C.
    Oncol Rep; 2011 May 03; 25(5):1481-7. PubMed ID: 21331448
    [Abstract] [Full Text] [Related]

  • 20. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
    Günthert AR, Gründker C, Böttcher B, Emons G.
    Anticancer Res; 2004 May 03; 24(3a):1727-32. PubMed ID: 15274347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.